ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
08 04 2020
Historique:
received: 14 01 2020
accepted: 18 03 2020
revised: 17 03 2020
entrez: 10 4 2020
pubmed: 10 4 2020
medline: 10 4 2021
Statut: epublish

Résumé

The apoptosis-stimulating protein of p53 (ASPP) family of proteins can regulate apoptosis by interacting with the p53 family and have been identified to play an important role in cancer progression. Previously, we have demonstrated that ASPP2 downregulation can promote invasion and migration by controlling β-catenin-dependent regulation of ZEB1, however, the role of ASPP1 in colorectal cancer (CRC) remains unclear. We analyzed data from The Cancer Genome Atlas (TCGA) and coupled this to in vitro experiments in CRC cell lines as well as to experimental pulmonary metastasis in vivo. Tissue microarrays of CRC patients with information of clinical-pathological parameters were also used to investigate the expression and function of ASPP1 in CRC. Here, we report that loss of ASPP1 is capable of enhancing migration and invasion in CRC, both in vivo and in vitro. We demonstrate that depletion of ASPP1 could activate expression of Snail2 via the NF-κB pathway and in turn, induce EMT; and this process is further exacerbated in RAS-mutated CRC. ASPP1 could be a prognostic factor in CRC, and the use of NF-κB inhibitors may provide new strategies for therapy against metastasis in ASPP1-depleted CRC patients.

Identifiants

pubmed: 32269211
doi: 10.1038/s41419-020-2415-2
pii: 10.1038/s41419-020-2415-2
pmc: PMC7142079
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Apoptosis Regulatory Proteins 0
PPP1R13B protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

224

Subventions

Organisme : Medical Research Council
ID : MR/S025480/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : SBF002\1038
Pays : United Kingdom

Références

Bergamaschi, D. et al. ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell. Biol. 24, 1341–1350 (2004).
pubmed: 14729977 pmcid: 321425 doi: 10.1128/MCB.24.3.1341-1350.2004
Bergamaschi, D. et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162–167 (2003).
pubmed: 12524540 doi: 10.1038/ng1070 pmcid: 12524540
Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8, 781–794 (2001).
pubmed: 11684014 doi: 10.1016/S1097-2765(01)00367-7 pmcid: 11684014
Trigiante, G. & Lu, X. ASPP and cancer. Nat. Rev. Cancer 6, 217–226 (2006).
pubmed: 16498444 doi: 10.1038/nrc1818 pmcid: 16498444
Chan, K. K. et al. Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma. BMC Cancer 19, 953 (2019).
pubmed: 31615473 pmcid: 6792270 doi: 10.1186/s12885-019-6206-z
Chan, K. K. et al. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. Int. J. Cancer 143, 1456–1469 (2018).
pubmed: 29663364 doi: 10.1002/ijc.31535 pmcid: 29663364
Mak, V. C. et al. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod. Pathol. 24, 522–532 (2011).
pubmed: 21102414 doi: 10.1038/modpathol.2010.216 pmcid: 21102414
Mak, V. C. et al. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis 34, 2170–2177 (2013).
pubmed: 23671128 doi: 10.1093/carcin/bgt161 pmcid: 23671128
Song, B. et al. Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol. Cancer 14, 177 (2015).
pubmed: 26438046 pmcid: 4594892 doi: 10.1186/s12943-015-0447-5
Wang, X. D. et al. SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ. 18, 304–314 (2011).
pubmed: 20798689 doi: 10.1038/cdd.2010.101 pmcid: 20798689
Wang, Y. et al. Autophagic activity dictates the cellular response to oncogenic RAS. Proc. Natl Acad. Sci. USA 109, 13325–13330 (2012).
pubmed: 22847423 doi: 10.1073/pnas.1120193109 pmcid: 22847423
Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 27, 347–376 (2011).
pubmed: 21740232 doi: 10.1146/annurev-cellbio-092910-154036 pmcid: 21740232
Stemmler, M. P., Eccles, R. L., Brabletz, S. & Brabletz, T. Non-redundant functions of EMT transcription factors. Nat. Cell Biol. 21, 102–112 (2019).
pubmed: 30602760 doi: 10.1038/s41556-018-0196-y pmcid: 30602760
Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275–292 (2011).
pubmed: 22000009 pmcid: 3261217 doi: 10.1016/j.cell.2011.09.024
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21–45 (2016).
pubmed: 27368099 doi: 10.1016/j.cell.2016.06.028 pmcid: 27368099
Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415–428 (2007).
pubmed: 17508028 doi: 10.1038/nrc2131 pmcid: 17508028
Kim, J. W. et al. Cytoplasmic iASPP expression as a novel prognostic indicator in oral cavity squamous cell carcinoma. Ann. Surg. Oncol. 22, 662–669 (2015).
pubmed: 25149434 doi: 10.1245/s10434-014-4003-0 pmcid: 25149434
Liu, W. K., Jiang, X. Y., Ren, J. K. & Zhang, Z. X. Expression pattern of the ASPP family members in endometrial endometrioid adenocarcinoma. Onkologie 33, 500–503 (2010).
pubmed: 20926896 doi: 10.1159/000319692 pmcid: 20926896
Liu, Z. J. et al. Downregulated mRNA expression of ASPP and the hypermethylation of the 5’-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 579, 1587–1590 (2005).
pubmed: 15757645 doi: 10.1016/j.febslet.2005.01.069 pmcid: 15757645
Morris, E. V. et al. Nuclear iASPP may facilitate prostate cancer progression. Cell Death Dis. 5, e1492 (2014).
pubmed: 25341046 pmcid: 4649527 doi: 10.1038/cddis.2014.442
Yin, L. et al. The family of apoptosis-stimulating proteins of p53 is dysregulated in colorectal cancer patients. Oncol. Lett. 15, 6409–6417 (2018).
pubmed: 29731851 pmcid: 5921073
Zhao, J. et al. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51, 142–153 (2010).
pubmed: 20034025 doi: 10.1002/hep.23247 pmcid: 20034025
Agirre, X. et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25, 1862–1870 (2006).
pubmed: 16314841 doi: 10.1038/sj.onc.1209236 pmcid: 16314841
Wang, C. et al. Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines. Cancer Cell Int. 13, 116 (2013).
pubmed: 24245874 pmcid: 4176745 doi: 10.1186/1475-2867-13-116
Wang, X. et al. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation. Int. J. Cancer 141, 1422–1433 (2017).
pubmed: 28656647 doi: 10.1002/ijc.30852 pmcid: 28656647
Wang, Y. et al. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1. Nat. Cell Biol. 16, 1092–1104 (2014).
pubmed: 25344754 doi: 10.1038/ncb3050 pmcid: 25344754
Wang, Y. et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29, 4658–4670 (2010).
pubmed: 20562906 doi: 10.1038/onc.2010.218 pmcid: 20562906
Shirasawa, S., Furuse, M., Yokoyama, N. & Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85–88 (1993).
pubmed: 8465203 doi: 10.1126/science.8465203 pmcid: 8465203
Hassanzadeh, P. Colorectal cancer and NF-κB signaling pathway. Gastroenterol. Hepatol. Bed Bench 4, 127–132 (2011).
pubmed: 24834170 pmcid: 4017424
Benyamini, H. & Friedler, A. The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins. J. Mol. Recognit. 24, 266–274 (2011).
pubmed: 20623514 doi: 10.1002/jmr.1048 pmcid: 20623514
Tiwari, M., Mikuni, S., Muto, H. & Kinjo, M. Determination of dissociation constant of the NFκB p50/p65 heterodimer using fluorescence cross-correlation spectroscopy in the living cell. Biochem. Biophys. Res. Commun. 436, 430–435 (2013).
pubmed: 23751347 doi: 10.1016/j.bbrc.2013.05.121 pmcid: 23751347
Yang, J.-P., Hori, M., Sanda, T. & Okamoto, T. Identification of a Novel Inhibitor of Nuclear Factor-κB, RelA-associated Inhibitor. J. Biol. Chem. 274, 15662–15670 (1999).
pubmed: 10336463 doi: 10.1074/jbc.274.22.15662 pmcid: 10336463
Min, C., Eddy, S. F., Sherr, D. H. & Sonenshein, G. E. NF-kappaB and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 104, 733–744 (2008).
pubmed: 18253935 doi: 10.1002/jcb.21695 pmcid: 18253935
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593 pmcid: 30207593 doi: 10.3322/caac.21492
Saeed, O. et al. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J. Clin. Pathol. 72, 135 (2019).
pubmed: 30425122 doi: 10.1136/jclinpath-2018-205471 pmcid: 30425122
Papke, B. & Der, C. J. Drugging RAS: Know the enemy. Science 355, 1158 (2017).
pubmed: 28302824 doi: 10.1126/science.aam7622 pmcid: 28302824
Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457 (2012).
pubmed: 22589270 pmcid: 3354961 doi: 10.1158/0008-5472.CAN-11-2612
Jinesh, G. G., Sambandam, V., Vijayaraghavan, S., Balaji, K. & Mukherjee, S. Molecular genetics and cellular events of K-Ras-driven tumorigenesis. Oncogene 37, 839–846 (2018).
pubmed: 29059163 doi: 10.1038/onc.2017.377 pmcid: 29059163
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467–1480 (2019).
pubmed: 31631858 doi: 10.1016/S0140-6736(19)32319-0 pmcid: 31631858
Brouwer, N. P. M. et al. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int. J. Cancer 143, 2758–2766 (2018).
pubmed: 30095162 pmcid: 6282554 doi: 10.1002/ijc.31785
Kanas, G. P. et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin. Epidemiol. 4, 283–301 (2012).
pubmed: 23152705 pmcid: 3496330
Khamas, A. et al. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2’-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteom. 9, 67–75 (2012).
Park, S. W., An, C. H., Kim, S. S., Yoo, N. J. & Lee, S. H. Mutational analysis of ASPP1 and ASPP2 genes, a p53-related gene, in gastric and cololorectal cancers with mcrosatellite instability. Gut Liver 4, 292–293 (2010).
pubmed: 20559540 pmcid: 2886944 doi: 10.5009/gnl.2010.4.2.292
Wei, W. L. et al. [Promoter methylation of ASPP1 and ASPP2 genes in non-small cell lung cancers]. Zhonghua Bing. Li Xue Za Zhi 40, 532–536 (2011).
pubmed: 22169642 pmcid: 22169642
Alves, C. C., Carneiro, F., Hoefler, H. & Becker, K. F. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front. Biosci. (Landmark Ed.) 14, 3035–3050 (2009).
doi: 10.2741/3433
Cobaleda, C., Perez-Caro, M., Vicente-Duenas, C. & Sanchez-Garcia, I. Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu. Rev. Genet. 41, 41–61 (2007).
pubmed: 17550342 doi: 10.1146/annurev.genet.41.110306.130146
Xia, Y., Shen, S. & Verma, I. M. NF-κB, an active player in human cancers. Cancer Immunol. Res. 2, 823–830 (2014).
pubmed: 25187272 pmcid: 4155602 doi: 10.1158/2326-6066.CIR-14-0112
Sakamoto, K. et al. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res. 15, 2248 (2009).
pubmed: 19276252 doi: 10.1158/1078-0432.CCR-08-1383 pmcid: 19276252
Baldwin, A. S. Jr The NF-kappa B. and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–683 (1996).
pubmed: 8717528 doi: 10.1146/annurev.immunol.14.1.649 pmcid: 8717528
Basseres, D. S. & Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817–6830 (2006).
pubmed: 17072330 doi: 10.1038/sj.onc.1209942 pmcid: 17072330
Dutta, J., Fan, Y., Gupta, N., Fan, G. & Gelinas, C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25, 6800–6816 (2006).
pubmed: 17072329 doi: 10.1038/sj.onc.1209938 pmcid: 17072329
Wu, Y. & Zhou, B. P. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br. J. Cancer 102, 639–644 (2010).
pubmed: 20087353 pmcid: 2837572 doi: 10.1038/sj.bjc.6605530
Li, C. W. et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72, 1290–1300 (2012).
pubmed: 22253230 pmcid: 3350107 doi: 10.1158/0008-5472.CAN-11-3123
Benyamini, H. et al. A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Proteins Struct. Funct. Bioinforma. 77, 602–611 (2009).
doi: 10.1002/prot.22473
Nirvanappa, A. C. et al. Novel synthetic oxazines target NF-κB in colon cancer in vitro and inflammatorybowel disease in vivo. PLoS ONE 11, e0163209 (2016).
pubmed: 27685808 pmcid: 5042377 doi: 10.1371/journal.pone.0163209
Samuel, T., Fadlalla, K., Gales, D. N., Putcha, B. D. K. & Manne, U. Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer 14, 599 (2014).
pubmed: 25134433 pmcid: 4152571 doi: 10.1186/1471-2407-14-599
Yu, W. et al. Formation of cysts by alveolar type II cells in three-dimensional culture reveals a novel mechanism for epithelial morphogenesis. Mol. Biol. Cell 18, 1693–1700 (2007).
pubmed: 17332496 pmcid: 1855040 doi: 10.1091/mbc.e06-11-1052

Auteurs

Dian Liu (D)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.

Ayse Ertay (A)

Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.

Charlotte Hill (C)

Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.

Yilu Zhou (Y)

Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.
Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.

Juanjuan Li (J)

Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.

Yanmei Zou (Y)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.

Hong Qiu (H)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.

Xianglin Yuan (X)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.

Rob M Ewing (RM)

Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.
Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK.

Xin Lu (X)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.

Hua Xiong (H)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China. cnhxiong@163.com.

Yihua Wang (Y)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China. yihua.wang@soton.ac.uk.
Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK. yihua.wang@soton.ac.uk.
Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK. yihua.wang@soton.ac.uk.
NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, SO16 6YD, UK. yihua.wang@soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH